Quess Corp, India’s leading business services provider, announced the launch of its new healthcare vertical to address the shortage of healthcare professionals.
The vertical aims to provide trained healthcare manpower, home care solutions, and end-to-end hospital management services by identifying, training & upskilling healthcare professionals through a network of accredited medical training institutes, enabling quick & on-demand deployment.
Quess Corp has signed an MoU with the Association of Healthcare Providers (India) (AHPI), a not-for-profit representative body of healthcare providers, to evangelize formalization of training and staffing services for healthcare professionals and create a talent marketplace for private and public healthcare institutions.
The collaboration aspires to create a pipeline of trained paramedical and healthcare service professionals through a proposed hire-train-deploy model, besides building a digital pool of highly skilled, experienced, ready-to-hire doctors across India.
In addition to creating an organized demand and supply support service for healthcare manpower such as nurses, paramedics, doctors, phlebotomists, and lab technicians, the collaboration will also enable corporates to set up safer workspaces with adequate medical facilities, and to train candidates with endorsements from reputed domestic and international accreditations. Through this alliance, Quess Corp and AHPI plan to jointly work towards industry advocacy in critical areas of staffing and healthcare manpower management.
Dr Naresh Shetty, president, Quess Healthcare said, “In India, the healthcare segment faces dismaying challenges with an acute shortage of skilled manpower to the tune of six million paramedics today. We hope to bridge this gap and indisputably impact skill development and knowledge enhancement of the healthcare sector, which is the absolute need of the hour. Through tech-enabled skilling and access to a talent pool of trained professionals, we want to empower healthcare providers to cater to a wide public reach while providing access to quality healthcare for all.”
Dr Giridhar Gyani, director general, AHPI said “Improving the Indian healthcare system by expanding basic healthcare access to the larger community has been our long-standing commitment at AHPI. We are pleased to partner with Quess Corporation, the leading manpower service company, and believe that together, we can successfully redesign and advocate for the medical ecosystem with trained and qualified workforce.”
A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.
The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.
On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.
Following a series of typhoon disruptions in East China during the month of August, major ports including Shanghai and Ningbo continue to experience congestion and operational recovery challenges. Industry reports indicate that vessel schedules, yard operations, and equipment circulation remain affected as terminals work through accumulated backlogs from successive storm events.
Under REACH Annex XVII Entry 78, the EU has banned the placing on the market of synthetic polymer microparticles (SPMs) unless a specific derogation applies. Derogations exist for essential uses such as:
As a result of the amendment of the CLP Regulation (Regulation (EC) No 1272/2008 on the classification, labelling and packaging of substances and mixtures), new hazard classes have entered into force.
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.
The global pharmaceutical fine chemicals sector is undergoing a profound transformation, with India emerging as a central growth engine amid sweeping changes in supply chain strategies and regulatory priorities. As drug makers and contract manufacturers adapt to stricter oversight and evolving sourcing preferences, the industry’s focus is shifting rapidly from cost efficiency to compliance, localisation and technical sophistication.
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.